Myovant Sciences Ltd.
MYOVDelisted Mar 10, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001679082
Myovant Sciences Ltd. was delisted on Mar 10, 2023; its insiders filed their last Form 4 on Mar 10, 2023; 118 institutions reported holding it in 13F filings for Q4 2022, worth $1.12B in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:55 PM ET
Revenue flow, FY2022
Where the revenue went in FY2022, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2022: $206.0M (89.2% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Period end | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | Mar 31, 2018 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | May 10, 2022 | May 11, 2021 | May 18, 2020 | May 24, 2019 | Jun 7, 2018 |
| Revenue | $231.0M | $59.3M | – | – | – |
| Operating expenses | – | – | $274.9M | $264.8M | $141.1M |
| Research and development | $107.4M | $136.7M | $192.6M | $222.6M | $116.8M |
| Selling, general and administrative | $259.4M | $181.4M | $82.3M | $42.2M | $24.2M |
| Operating income | -$187.3M | -$260.8M | – | -$273.1M | -$143.0M |
| Interest expense | $14.0M | $10.4M | – | $8.82M | $2.05M |
| Income tax | $5.05M | $336.0K | $761.0K | $476.0K | $213.0K |
| Net income | -$206.0M | -$255.1M | -$289.0M | -$273.6M | -$143.3M |
| EPS, basic | $-2.22 | – | – | – | – |
| EPS, diluted | $-2.22 | – | – | – | – |
| Weighted shares, basic | 93.0M | – | – | – | – |
| Weighted shares, diluted | 93.0M | – | – | – | – |
| Margins and growth | |||||
| Operating margin | -81.1% | -439.6% | – | – | – |
| Net margin | -89.2% | -430.1% | – | – | – |
| Revenue growth, year over year | +289.4% | – | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Period end | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | Mar 31, 2018 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | May 10, 2022 | May 11, 2021 | May 18, 2020 | May 24, 2019 | Jun 7, 2018 |
| Cash and equivalents | $406.7M | $674.5M | $76.6M | $156.1M | $108.6M |
| Short-term investments | $27.5M | $10.4M | $3.00M | – | – |
| Accounts receivable | $23.3M | $3.57M | – | – | – |
| Inventory | $7.58M | $2.61M | – | – | – |
| Total current assets | $488.1M | $704.6M | $87.9M | $166.8M | $114.8M |
| Property, plant and equipment | $2.94M | $3.30M | $2.50M | $2.07M | $1.27M |
| Total assets | $520.0M | $725.0M | $105.9M | $173.0M | $119.1M |
| Accounts payable | $12.3M | $17.8M | $15.3M | – | $4.58M |
| Short-term debt | – | – | $0 | $6.14M | – |
| Total current liabilities | $250.3M | $281.3M | $85.9M | $72.0M | $37.1M |
| Long-term debt | – | – | $0 | $93.2M | $43.6M |
| Total liabilities | $993.5M | $1.08B | $214.2M | $168.6M | $81.4M |
| Shareholders' equity | -$473.5M | -$354.0M | -$108.3M | $4.33M | $37.7M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Period end | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | Mar 31, 2018 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | May 10, 2022 | May 11, 2021 | May 18, 2020 | May 24, 2019 | Jun 7, 2018 |
| Operating cash flow | -$268.6M | $370.6M | -$221.2M | -$224.1M | -$117.3M |
| Capital expenditures | $974.0K | $1.77M | $1.10M | $1.24M | $604.0K |
| Free cash flow | -$269.5M | $368.9M | -$222.3M | -$225.3M | -$117.9M |
| Depreciation and amortization | – | – | $1.76M | – | – |
| Stock-based compensation | $38.9M | $53.7M | $40.3M | $18.7M | $11.6M |
| Investing cash flow | -$18.0M | -$9.21M | -$3.94M | -$1.24M | -$604.0K |
| Financing cash flow | $25.9M | $238.0M | $145.9M | $273.9M | $45.6M |
| Net change in cash | -$260.7M | $599.5M | -$79.2M | $48.6M | -$72.2M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 16.9% | 90.5% | – | – | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Jan 20, 2023 | 97.2M | +3.5% | SEC |
| Oct 21, 2022 | 96.8M | +3.7% | SEC |
| Jul 25, 2022 | 95.9M | +4.2% | SEC |
| May 6, 2022 | 95.3M | +4.2% | SEC |
| Jan 21, 2022 | 93.9M | +3.4% | SEC |
| Oct 22, 2021 | 93.3M | +3.0% | SEC |
| Jul 23, 2021 | 92.1M | +2.1% | SEC |
| May 6, 2021 | 91.5M | +1.8% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.